

Literatura ACTA MEDICINAE 14/2019 Farmakologická léčba

- 2 **Osimertinib – finální data celkového přežití ze studie FLAURA, sekvence léčby TKI EGFR inhibitory**
MUDr. Jaromír Roubec, Ph.D. Vítkovická nemocnice, a. s., člen skupiny AGEL, KOC Nový Jičín
- 2 **Pembrolizumab v léčbě nemalobuněčného plicního karcinomu**
MUDr. Petra Zemanová | MUDr. Renata Jirásková | doc. MUDr. Milada Zemanová Ph.D.
Onkologická klinika VFN a 1. LF UK, I. klinika tuberkulózy a respiračních nemocí VFN a 1. LF UK, Praha
MUDr. Ilona Roušalová I. klinika tuberkulózy a respiračních nemocí VFN a 1. LF UK, Praha
- 2 **CDK4/6 inhibitory prodlužují také čas do druhé progrese (PFS2) – studie MONALEESA-3 a MONALEESA-7**
prof. MUDr. Petra Tesařová, CSc. Onkologická klinika 1. LF UK a VFN, Praha
- 2 **Léčba metastatického hormon dependentního karcinomu prsu inhibitory CDK4/6**
MUDr. Věra Benešová Komplexní onkologické centrum, Nemocnice Jihlava
- 2 **Apalutamid v léčbě nemetastatického kastročně refrakterního karcinomu prostaty**
MUDr. Hana Študentová, Ph.D. Onkologická klinika, FN Olomouc
- 3 **ERAS (Enhanced Recovery After Surgery) a sugammadex**
doc. MUDr. Tomáš Vymazal, Ph.D., MHA KARIM 2. LF UK a FN v Motole, Praha
- 3 **K translačnímu výzkumu depresí**
prof. MUDr. Alexandra Šulcová, CSc., FCMA, FECNP, FCINP International Cannabis and Cannabinoid Institute, Praha
- 3 **Personalizovaná léčba antipsychotiky**
prof. MUDr. Eva Češková, CSc. CEITEC-MU, Psychiatrická klinika FN Brno, KNP LF University Ostrava, Oddělení psychiatrie FN Ostrava
- 3 **Depresivní porucha u nemocných s psoriázou**
prof. MUDr. Jiří Horáček, Ph.D., FCMA Národní ústav duševního zdraví, Klecany, 3. LF UK, Praha
- 4 **Plzeň se stala místem setkání špičkových světových odborníků v oblasti HIV**
- 4 **EndWarts FREEZE – lékový profil**
MUDr. Jan Hugo Dermatovenerologická klinika 3. LF UK a FNKV, Praha
- 4 **Lékové interakce v gastroenterologii**
doc. PharmDr. Jan Juřica, Ph.D. Farmakologický ústav, LF MU; Ústav humánní farmakologie a toxikologie Farmaceutické fakulty VFU; Ústavní lékárna, Masarykův onkologický ústav, Brno
- 4 **Diozen – lékový profil**
MUDr. Helena Čermáková Cévní ambulance, Klinika transplantační chirurgie IKEM, Praha
- 4 **Z první prospektivní studie podávání biologického přípravku v reálné klinické praxi plyne, že přípravek Nucala významně snižuje exacerbace těžkého eozinofilního astmatu – advertorial**
Výsledky předběžné analýzy studie REALITI-A prezentované na kongresu Evropské respirační společnosti
- 5 **Asthma bronchiale prizmatem moderní farmakoterapie**
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 5 **Vitamin D – proč suplementovat?**
prof. MUDr. Ondřej Topolčan, CSc. | doc. PharmDr. Radek Kučera, Ph.D. Oddělení imunochemické diagnostiky, Fakultní nemocnice Plzeň, Centrální laboratoř pro imunoanalýzu, Lékařská fakulta v Plzni, Univerzita Karlova
- 5 **Fingolimod v léčbě relaps-remitující formy sclerosis multiplex –studie ASSESS**
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

Osimertinib – finální data celkového přežití ze studie FLAURA, sekvenční léčby TKI EGFR inhibitory

MUDr. Jaromír Roubec, Ph.D. Vítkovická nemocnice, a. s., člen skupiny AGEL, KOC Nový Jičín

- 1 Ramalingam, S. S. – Gray, J. E. – Ohe, Y., et al.: Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFR ma NSCLC (FLAURA): Final OS analysis [přednáška]. Prezentováno na ESMO; 27. 9.– 1. 10. 2019, Barcelona, Španělsko, abstrakt LBA5.
- 2 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for NSCLC V.7.2019. National Comprehensive Cancer Network, Inc. 2019. Allrights reserved. Přístup 2. 11. 2019.
- 3 ESMO – The European Society for Medical Oncology, aktualizovaná data publikována 18. 9. 2019 na ESMO Guidelines Committee, vyhledáno 2. 11. 2019.
- 4 Wang, Z. F. – Ren, S. X. – Li, W., et al.: Frequency of the acquired resistant mutation T790M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis. *BMC Cancer*, 2018, 18, s. 148, <https://doi.org/10.1186/s12885-018-4075-5>.
- 5 Hochmair, M. J. – Morabito, A. – Hao, D., et al.: Afatinib followed by osimertinib in patients with EGFR mutation positive (EGFR m+) advanced NSCLC: updated data from the GioTag real world study. *Future Oncol*, 2019, 15s. 2905–2914.
- 6 Shah, R. – Girard, N. – Nagar, S. P., et al.: Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC receiving a firstline (1L) first- or second-generation (1G/2G) EGFR tyrosine kinase inhibitor (TKI). 1522P. Prezentováno na ESMO; 27. 9.– 1. 10. 2019, Barcelona, Španělsko.

Pembrolizumab v léčbě nemalobuněčného plicního karcinomu

MUDr. Petra Zemanová | MUDr. Renata Jirásková | doc. MUDr. Milada Zemanová Ph.D.

Onkologická klinika VFN a 1. LF UK, I. klinika tuberkulózy a respiračních nemocí VFN a 1. LF UK, Praha

MUDr. Ilona Roušalová I. klinika tuberkulózy a respiračních nemocí VFN a 1. LF UK, Praha

- 1 Brahmer, J. – Rodriguez-Abreu, D. – Robinson, A., et al.: OA 17.06 Updated Analysis of KEYNOTE-024: Pembrolizumab vs platinum-based chemotherapy for advanced NSCLC with PD-L1 TPS $\geq 50\%$. *J Thor Oncol*, 12, s. S1793–S1794.
- 2 Reck, M. – Rodriguez-Abreu, D. – Robinson, A. G., et al.: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *N Engl J Med*, 2016, 375, s. 1823–1833.

CDK4/6 inhibitory prodlužují také čas do druhé progresse (PFS2) – studie MONALEESA-3 a MONALEESA-7

prof. MUDr. Petra Tesařová, CSc. Onkologická klinika 1. LF UK a VFN, Praha

- 1 Slamon, D. J. – Neven, P. – Chia, S. K. L., et al.: Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): results from MONALEESA-3. *J Clin Oncol*, 2019, 37, suppl., abstrakt 1000.
- 2 Slamon, D. J. – Neven, P. – Chia, S., et al.: Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) + ribociclib (rib). Prezentováno na 2019 ESMO Congress; 27. 9.– 1. 10. 2019; Barcelona, Španělsko. Abstrakt LBA7.
- 3 Hurvitz, S. A. – Im, S.-A. – Lu, Y.-S., et al.: Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2- advanced breast cancer (ABC) treated with endocrine therapy \pm ribociclib: Overall survival (OS) results. *J Clin Oncol*, 2019, 37, suppl., abstrakt LBA1008.
- 4 Im, S. A., et al.: Overall survival with ribociclib plus endocrine therapy in breast cancer. *N Engl J Med*, 2019, 381, s. 307–316.

Léčba metastatického hormon dependentního karcinomu prsu inhibitory CDK4/6

MUDr. Věra Benešová Komplexní onkologické centrum, Nemocnice Jihlava

- 1 Finn, R. S., et al.: Abstract CT 101. Final result of a randomized phase II study of PD 033299 a cyclin-dependent kinase (CDK)-4/6 inhibitor in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2-advanced breast cancer (PALOMA-1 TRI018). *Cancer Research*, 2014, 74.19, suppl.
- 2 Finn, R. S., et al.: Palbociclib and letrozole in advanced breast cancer. *N Engl J Med*, 2016, 375, s. 1925–1936.
- 3 Cristofani, M., et al.: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor positive HER-2 negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3). Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol*, 2016, 17, s. 425–439.
- 4 Hortobagyi, G. N., et al.: Ribociclib as first-line therapy for HR-positive, advanced breast cancer. *N Engl J Med*, 2016, 375, s. 1738–1748.
- 5 Dickler, M. N., et al.: MONARCH 1: Results from a phase II study of abemaciclib a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease. Prezentováno na kongresu ASCO, 3. 6. 2016, abstrakt 510.
- 6 Dickson, M. A. – Schwartz, G. K.: Development of cell-cycle inhibitors for cancer therapy. *Curr Oncol*, 2009, 16, s. 36–43.

Apalutamid v léčbě nemetastatického kastročně refrakterního karcinomu prostaty

MUDr. Hana Študentová, Ph.D. Onkologická klinika, FN Olomouc

- 1 Amling, C. L. – Bergstralh, E. J. – Blute, M. L., et al.: Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? *J Urol*, 2001, 165, s. 1146–1151.
- 2 Esther, J. – Maughan, B. L. – Anderson, N., et al.: Management of nonmetastatic castration-resistant prostate cancer: recent advances and future directions. *Curr Treat Options Oncol*, 2019, 20, s. 14.
- 3 Miyake, H. – Hara, I. – Eto, H.: Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. *BJU Int*, 2005, 96, s. 791–795.
- 4 Sartor, A. O. – Tangen, C. M. – Hussain, M. H., et al.: Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest oncology group trial (SWOG 9426). *Cancer*, 2008, 112, s. 2393–2400.
- 5 Smith, M. R. – Kabbinavar, F. – Saad, F., et al.: Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. *J Clin Oncol*, 2005, 23, s. 2918–2925.
- 6 NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. Version 4.2019. National Comprehensive Cancer Network; 19. 8. 2019, vyhledáno 15. 11. 2019.
- 7 Smith, M. R. – Saad, F. – Oudard, S., et al.: Denosumab and bone metastasis-free survival in men with non-metastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. *J Clin Oncol*, 2013, 31, s. 3800–3806.
- 8 Clegg, N. J. – Wongvipat, J. – Joseph, J. D., et al.: ARN-509: a novel antiandrogen for prostate cancer treatment. *Cancer Res*, 2012, 72, s. 1494–1503.
- 9 Smith, M. R. – Saad, F. – Chowdhury, S., et al.: Apalutamid treatment and metastasis-free survival in prostate cancer. *N Engl J Med*, 2018, 378, s. 1408–1418.
- 10 Small, E. J. – Saad, F. – Chowdhury, S., et al.: Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamid (APA) in patients (pts) with high-risk non metastatic castration-resistant prostate cancer (mCRPC). *J Clin Oncol*, 2019, 37, suppl., s. 144.
- 11 Small, E. J. – Saad, F. – Chowdhury, S., et al.: Apalutamid and overall survival in non-metastatic castration-resistant prostate cancer. *Ann Oncol*, 2017, 29, pii: mdz397.
- 12 Hussain, M. – Fizazi, K. – Saad, F., et al.: Enzalutamid in men with nonmetastatic, castration-resistant prostate cancer. *N Engl J Med*, 2018, 378, s. 2465–2474.
- 13 Fizazi, K. – Shore, N. – Tammela, T. L., et al.: Darolutamid in non-metastatic, castration-resistant prostate cancer. *N Engl J Med*, 2019, 380, s. 1235–1246.
- 14 Watson, P. A. – Arora, V. K. – Sawyers, C. L.: Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. *Nature Rev Cancer*, 2015, 15, s. 701–711.
- 15 Rathkopf, D. E. – Smith, M. R. – Ryan, C. J., et al.: Androgen receptor in hormone-dependent and castration-resistant prostate cancer treated with apalutamid. *Ann Oncol*, 2017, 28, s. 2264–2271.

ERAS (Enhanced Recovery After Surgery) a sugammadex

doc. MUDr. Tomáš Vymazal, Ph.D., MHA KARIM 2. LF UK a FN v Motole, Praha

- Vymazal, T.: Koncept ERAS (Enhanced Recovery After Surgery). *Postgraduální medicína*, 2018, 5, s. 453–455.
- Vymazal, T.: ERAS (420-3). In: Vymazal, T. – Michálek, P., et al.: *Anestezie a pooperační péče v hrudní chirurgii*. 2016, Mladá fronta, Praha.
- Ljungqvist, O.: ERAS – Enhanced recovery after surgery: moving evidence-based perioperative care to practice. *J Parenter Enteral Nutr*, 2014, 38, s. 559–566.
- Ljungqvist, O. – Scott, M. – Fearon, K. C.: Enhanced recovery after surgery: a review. *JAMA Surg*, 2017, 152, s. 292–298.
- Kehlet, H.: ERAS implementation-time to move forward. *Ann Surg*, 16. 2. 2018.
- Kehlet, H. – Joshi, G. P.: Enhanced recovery after surgery: current controversies and concerns. *Int Anesth Res Soc*, 2017, 125, s. 2154–2155.
- MacFie, J.: Enhanced recovery after surgery is obsolete. *Dis Colon Rectum*, 2016, 59, s. 1002–1003.
- Cerný, V. – Adamus, M. – Cvachovec, K. – Ševčík, P. – Herold, I.: Anestezie v České republice 2010 – jednodenní prospektivní observační dotazníková studie. *Anest Intenziv Med*, 2011, 22, s. 5–12.
- Blobner, M., et al.: Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomized controlled trial. *Eur J Anaesthesiol*, 2010, 27, s. 874–881.
- Berg, H. – Roed, J., et al.: Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. *Acta Anaesthesiol Scand*, 1997, 41, s. 1095–1103.
- Bartkowski, R. R.: Incomplete reversal of pancuronium neuromuscular blockade by neostigmine, pyridostigmine, and edrophonium. *Anesth Analg*, 1987, 66, s. 594–598.
- Murphy, G. S.: Residual neuromuscular blockade: incidence, assessment, and relevance in the postoperative period. *Minerva Anestesiologica*, 2006, 72, s. 97–109.
- Vymazal, T. – Horáček, M. – Bicek, V. – Filau, M.: Myasthenia gravis a anestezie – nový, bezpečnější postup. *Anest Intenziv Med*, 2014, 25, s. 21–24.
- Rahe-Meyer, N. – Fennema, H. – Schulman, S., et al.: Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. *Anesthesiology*, 2014, 121, s. 969–977.
- de Souza, C. M. – Tardelli, M. A. – Tedesco, H., et al.: Efficacy and safety of sugammadex in the reversal of deep neuromuscular blockade induced by rocuronium in patients with end-stage renal disease: A comparative prospective clinical trial. *Eur J Anaesthesiol*, 2015, 32, s. 681–686.
- Tsur, A. – Kalansky, A.: Hypersensitivity associated with sugammadex administration: a systematic review. *Anaesthesia*, 2014, 69, s. 1251–1257.
- Kotake, Y. – Ochiai, R. – Suzuki, T., et al.: Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block. *Anesth Analg*, 2013, 117, s. 345–351.
- Meistelman, C. – Donati, F.: Do we really need sugammadex as an antagonist of muscle relaxants in anesthesia? *Curr Opin Anaesthesiol*, 2016, 29, s. 462–467.

K translačnímu výzkumu depresí

prof. MUDr. Alexandra Šulcová, CSc., FCMA, FECNP, FCINP International Cannabis and Cannabinoid Institute, Praha

- Kršíak, M.: Ethopharmacology: A historical perspective. *Neurosci Biobehav Rev*, 1991, 15, s. 439–445.
- Leonard, B. E.: The olfactory bulbectomized rat as a model of depression. *Pol J Pharmacol Pharm*, 1984, 36, s. 561–569.
- Porsolt, R. D. – Le Pichon, M. – Jalfre, M.: Depression: a new animal model sensitive to antidepressant treatments. *Nature*, 1977, 266, s. 730–732.
- Willner, P. – Muscat, R. – Papp, M.: Chronic mild stress-induced anhedonia: a realistic animal model of depression. *Neurosci Biobehav Rev*, 1992, 16, s. 525–534.
- Geyer, M. A. – Markou, A.: The role of preclinical models in the development of psychotropic drugs. In: Davis, K. L. – Charney, D. – Coyle, J. T., et al.: *Nemeroff, C. (eds.): Neuropsychopharmacology: The Fifth Generation of Progress*. Lippincott Williams & Wilkins, Philadelphia, 2002, s. 445–455.
- Pistovcakova, J. – Sulcova, A. (a): Comparison of the effects of cannabidiol in two mouse models. Abstracts. Tallinn, Estonsko, CINP, 2006, s. 56.
- Pistovčáková, J. – Šulcová, A. (b): Antidepressive-like cannabidiol effects on exploratory behaviour in mice. *Homeostasis in Health and Diseases*, 2006, 44, s. 126–128.
- Resstel, L. B. – Tavares, R. F. – Lisboa, S. F., et al.: 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. *Br J Pharmacol*, 2009, 156, s. 181–188.
- Zanelati, T. V. – Biojone, C. – Moreira, F. A., et al.: Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. *Br J Pharmacol*, 2010, 159, s. 122–128.
- Micalo, V. – Di Marzo V. – Sulcova A., et al.: Endocannabinoid system and mood disorders: priming a target for new therapies. *Pharmacol Therap*, 2013, 13, s. 18–37.
- Micalo, V. – Tabiova, K. – Kucerova, J., et al.: Role of the endocannabinoid system in depression: from preclinical to clinical evidence. In: Campolongo, P. – Fattore, L.: *Cannabinoid Modulation of Emotion, Memory, and Motivation*. Springer, New York, 2015, s. 97–129.
- Stampanoni Bassi, M. – Gillo, L. – Maffei, P., et al.: Exploiting the multifaceted effects of cannabinoids on mood to boost their therapeutic use against anxiety and depression. *Front Mol Neurosci*, 2018, 11, s. 424.
- Premoli, M. – Aria, F. – Bonini, S. A., et al.: Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment. *Life Sci*, 2019, 224, s. 120–127.
- Sales, A. J. – Foqaca, M. – Sartim, A., et al.: Cannabidiol induces rapid and sustained antidepressant-like effects through increased BDNF signaling and synaptogenesis in the prefrontal cortex. *Molecular Neurobiol*, 2019, 56, s. 1070–1108.
- Kasper, S. – Frazer, A.: Editorial for treatment-resistant depression (TRD). *Int J Neuropsychopharmacol*, 2019, 22, s. 83–84.
- Willner, P. – Belzung, C.: Treatment-resistant depression: are animal models of depression fit for purpose? *Psychopharmacol (Berl)*, 2015, 232, s. 3473–3495.
- Willner, P. – Gruca, P. – Lason, M., et al.: Validation of chronic mild stress in the Wistar-Kyoto rat as an animal model of treatment-resistant depression. *Behav Pharmacol*, 2019, 30, s. 239–250.
- Réus, G. Z. – de Moura, A. B. – Borba, L. A., et al.: Strategies for treatment-resistant depression: lessons learned from animal models. *Mol Neuropsychiatry*, 2019, 5, s. 178–189.

Personalizovaná léčba antipsychotiky

prof. MUDr. Eva Češková, CSc. CEITEC-MU, Psychiatrická klinika FN Brno, KNP LF University Ostrava, Oddělení psychiatrie FN Ostrava

- Javitt, D. C.: Twenty-five years of glutamate in schizophrenia: are we there yet? *Schizophr Bull*, 2012, 38, s. 911–913.
- Dauvermann, M. R. – Lee, G. – Dawson, N.: Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research. *Br J Pharmacol*, 2017, 174, s. 3136–3160.
- Češková, E.: Současnost a budoucnost farmakoterapie závažných psychických poruch. *Čas Lék Čes*, 2018, 157, s. 96–100.
- Češková, E. – Hosák, L.: Individualizace farmakologické léčby v psychiatrii – zaostřeno na schizofrenii. *Acta medica*, 2014, 11, s. 62–64.
- Ceskova, E. – Silhan, P.: Novel treatment options in depression and psychosis. *Neuropsychiatr Dis Treat*, 2018, 14, s. 741–747.
- Prikryl, R. – Ceskova, E. – Kasperek, T. – Kucerova, H.: Neurological soft signs, clinical symptoms and treatment reactivity in patients suffering from first episode schizophrenia. *J Psychiatry Res*, 2006, 40, s. 141–146.
- Galderisi, S. – Mucci, A. – Buchanan, R. W., et al.: Negative symptoms of schizophrenia: new developments and unanswered research questions. *Lancet Psychiatry*, 2018, 5, s. 664–677.
- Hasan, A. – Falkai, P. – Wobrock, T., et al.: World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. *World J Biol Psychiatry*, 2013, 14, s. 2–44.
- Németh, G. – Laszlovsky, I. – Czobor, P., et al.: Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. *Lancet*, 2017, 389, s. 1103–1113.
- Earley, W. – Burgess, M. V. – Rekeka, L., et al.: Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study. *Am J Psychiatry*, 2019, 176, s. 439–448.
- Cerveri, G. – Gesi, C. – Mencacci, C.: Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm. *Neuropsychiatr Dis Treat*, 2019, 15, s. 1525–1535.
- Zhu, Y. – Li, C. – Huhn, M., et al.: How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis. *Eur Neuropsychopharmacol*, 2017, 27, s. 835–844.
- Masopust J. – Kopeček, M. – Protopopová D.: Sledování tělesného zdraví u pacientů se závažnými neorganickými duševními poruchami. V: Doporučené postupy psychiatrické péče 2018: Obecná psychiatrie, www.psychiatrie.cz.
- Hiemke, C. – Bergemann, N. – Clement, H. W., et al.: Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. *Pharmacopsychiatry*, 2018, 51, s. 9–62.
- Lenz, T. – Malhotra, A. K.: Pharmacogenetics of antipsychotic-induced side effects. *Dialogues Clin Neurosci*, 2009, 11, s. 405–415.
- Ravyn, D. – Ravyn, V. – Lowney, R., et al.: CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence. *Schizophr Res*, 2013, 149, s. 1–14.
- de With, S. A. J. – Pulit, S. L. – Staal, W. G., et al.: More than 25 years of genetic studies of clozapine-induced agranulocytosis. *Pharmacogenomics J*, 2017, 17, s. 304–311.
- Fernandes, B. S. – Williams, L. M. – Steiner, J., et al.: The new field of 'precision psychiatry'. *BMC Med*, 2017, 15, s. 80.
- Perlis, R. H.: Abandoning personalization to get to precision in the pharmacotherapy of depression. *World Psychiatry*, 2016, 15, s. 228–235.
- Menke A.: Precision pharmacotherapy: psychiatry's future direction in preventing, diagnosing, and treating mental disorders. *Pharmgenomics Pers Med*, 2018, 11, s. 211–222.

Depresivní porucha u nemocných s psoriázou

prof. MUDr. Jiří Horáček, Ph.D., FCMA Národní ústav duševního zdraví, Klecany, 3. LF UK, Praha

- Levis, B. – Yan, X. W. – He, C., et al.: Comparison of depression prevalence estimates in meta-analyses based on screening tools and rating scales versus diagnostic interviews: a meta-research review. *BMC Med*, 2019, 17, s. 65.
- Winkler, P. – Horáček, J. – Weisssova, A., et al.: Physical comorbidities in depression co-occurring with anxiety: a cross sectional study in the Czech primary care system. *Int J Environ Res Public Health*, 2015, 12, s. 15728–15738
- Rabin, F. – Bhuiyan, S. I. – Islam, T., et al.: Psychiatric and psychological

- comorbidities in patients with psoriasis – a review. *Mymensingh Med J*, 2012, 21, s. 780–786.
- Otte, C. – Gold, S. M. – Penninx, B. V., et al.: Major depressive disorder. *Nat Rev Dis Primers*, 2016, 2, 16065.
 - Rieder, E. – Tausk, F.: Psoriasis, a model of dermatologic psychosomatic disease: psychiatric implications and treatments. *Int J Dermatol*, 2012, 51, s. 12–26.
 - Kimball, A. B. – Guérin, A. – Tsaneva, M., et al.: Economic burden of comorbidities in patients with psoriasis is substantial. *J Eur Acad Dermatol Venereol*, 2011, 25, s. 157–163.
 - Jowett, S. – Ryan, T.: Skin disease and handicap: an analysis of the impact of skin conditions. *Soc Sci Med*, 1985, 20, s. 425–429.
 - Gonzalez-Parra, S. – Daudén, E.: Psoriasis and depression: the role of inflammation. *Actas Dermosifiliogr*, 2019, 110, s. 12–19.
 - Sjahir, M. – Roesyanto-Mahadi, I. D. – Effendy, E.: Correlation between serum brain-derived neurotrophic factor level and depression severity in psoriasis vulgaris patients. *Open Access Maced J Med Sci*, 2019, 7, s. 583–586.
 - Ikoma, Y. – Suhara, T. – Toyama, H., et al.: Quantitative analysis for estimating binding potential of the brain serotonin transporter with [¹¹C]McN5652. *J Cereb Blood Flow Metab*, 2002, 22, s. 490–501.
 - Kimball, A. B. – Jacobson, C. S. – Weiss, S., et al.: The psychosocial burden of psoriasis. *Am J Clin Dermatology*, 2005, 6, s. 383–392.
 - Polenghi, M. M. – Molinari, E. – Gala, C., et al.: Experience with psoriasis in a psychosomatic dermatology clinic. *Acta Derm Venereol Suppl* (Stockh), 1994, 186, s. 65–66.
 - Jin, W. – Zhang, S. – Duan, Y.: Depression symptoms predict worse clinical response to etanercept treatment in psoriasis patients. *Dermatology*, 2019, 235, s. 55–64.
 - Gupta, M. A. – Schork, N. J. – Gupta, A. K., et al.: Suicidal ideation in psoriasis. *Int J Dermatol*, 1993, 32, s. 188–190.
 - Gupta, M. A. – Gupta, A. K.: Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. *Br J Dermatol*, 1998, 139, s. 846–850.
 - Zung, W. W.: A self-rating Depression scale. *Arch Gen Psychiatry*, 1965, 12, s. 63–70.
 - Kroenke, K. – Spitzer, R. L. – Williams, J. B.: The Patient Health Questionnaire-2: validity of a two-item depression screener. *Med Care*, 2003, 41, s. 1284–1292.
 - Piepenburg, S. M. – Faller, H. – Gelbrich, G., et al.: Comparative potential of the 2-item versus the 9-item patient health questionnaire to predict death or rehospitalization in heart failure. *Circ Heart Fail*, 2015, 8, s. 464–472.
 - Dauden, E. – Blasco, A. J. – Bonanad, C., et al.: Position statement for the management of comorbidities in psoriasis. *J Eur Acad Dermatol Venereol*, 2018, 32, s. 2058–2073.
 - Fleming, P. – Roubille, C. – Richer, V., et al.: Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. *J Eur Acad Dermatol Venereol*, 2015, 29, s. 1063–1070.
 - Trivedi, M. H. – Rush, A. J. – Wisniewski, S. R., et al.: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. *Am J Psychiatry*, 2006, 163, s. 28–40.
 - Štětkařová, I. – Horáček, J.: Deprese u vybraných neurologických onemocnění. *Cesk Slov Neurol N*, 2016, 79/112, s. 626–638.
 - D'Erme, A. M. – Zanieri, F. – Campolmi, E., et al.: Therapeutic implications of adding the psychotropic drug escitalopram in the treatment of patients suffering from moderate-severe psoriasis and psychiatric comorbidity: a retrospective study. *J Eur Acad Dermatol Venereol*, 2014, 28, s. 246–249.
 - Lebwohl, M. G. – Papp, K. A. – Marangell, L. B., et al.: Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. *J Am Acad Dermatol*, 2018, 78, s. 81–89.

Plzeň se stala místem setkání špičkových světových odborníků v oblasti HIV

- Smit, M. – Brinkman, K. – Geerlings, S., et al.: Future challenges for clinical care of an ageing population infected with HIV: a modelling study. *Lancet Infect Dis*, 2015, 15, s. 810–818.
- Darbyshire, J. H. – Delta Coordinating Committee: Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. *Lancet*, 1996, 348, s. 283–291.

EndWarts FREEZE – lékový profil

MUDr. Jan Hugo Dermatovenerologická klinika 3. LF UK a FNKV, Praha

- Zalaudek, I., et al.: Entodermoscopy: a new tool for diagnosing skin infections and infestations. *Dermatology*, 2008, 216, s. 14–23.
- Sterling, J. C., et al.: British Association of Dermatologists' guideline for the management of cutaneous warts. *Br J Dermatol*, 2014, 171, s. 696–712.
- Walczuk, I., et al.: Efficacy and safety of three cryotherapy devices for wart treatment: a randomized, controlled, investigator-blinded, comparative study. *Dermatol Ther* (Heidelb), 2018, 8, s. 203–216.
- Andrews, M. D.: Cryosurgery for common skin conditions. *Am Fam Physician*, 2004, 69, s. 2365–2372.

Lékové interakce v gastroenterologii

doc. PharmDr. Jan Juřica, Ph.D. Farmakologický ústav, LF MU; Ústav humánní farmakologie a toxikologie Farmaceutické fakulty VFU; Ústavní lékárna, Masarykův onkologický ústav, Brno

- Bates, D. W. – Spell, N. – Cullen, D. J., et al.: The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. *JAMA*, 1997, 277, s. 307–311.
- Lazarou, J. – Pomeranz, B. H. – Corey, P. N.: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *JAMA*, 1998, 279, s. 1200–1205.
- Egan, L.: Drug interactions in gastroenterology: mechanisms, consequences, and how to avoid. *Clin Gastroenterol Hepatol*, 2004, 2, s. 725–730.
- Doligalski, C. T. – Tong Logan, A. – Silverman, A.: Drug interactions: a primer for the gastroenterologist. *Gastroenterol Hepatol*, 2012, 8, s. 376–383.
- Michalets, E.: Update: Clinically significant cytochrome P-450 drug interactions. *Pharmacotherapy*, 1998, 18, s. 84–112.
- Reimche, L. – Forster, A. J. – van Walraven, C.: Incidence and contributors to potential drug-drug interactions in hospitalized patients. *J Clin Pharmacol*, 2011, 51, s. 1043–1050.
- Dynamed: Dynamed. In., 03-2017 edn. Ipswich (MA): EBSCO Information Services. 1995–2018; 2019.
- Ritter, J. – Flower, R. – Henderson, G., et al.: da Rang & Dale's Pharmacology, 8E, vol. 8. Edinburgh; New York Elsevier/Churchill Livingstone; 2018, s. 776.
- Anzenbacher, P. – Anzenbacherová, E.: Cytochromes P450 and metabolism of xenobiotics. *Cell Mol Life Sci*, 2001, 58, s. 737–747.
- InfoPharm: AISLP. In.; 2019, www.aislp.cz.
- Drug Interactions. Cytochrome P450. Department of Medicine Clinical Pharmacology. Indiana University. Dostupné z: <https://drug-interactions.medicine.iu.edu/Home.aspx>, vyhledáno 14. 10. 2019.
- Nelson, D. R.: The cytochrome P450 homepage. *Hum Genomics*, 2009, 4, s. 59–65.
- Drug Interaction Checker. Dostupné z: https://www.drugs.com/drug_interactions.html, vyhledáno 14. 10. 2019.
- Lukáš, M.: Polymorbidní senior z pohledu gastroenterologa. *Medicina pro praxi*, 2013, 10, s. 300–303.
- Rychlíková, J.: Následky hypoacidit navozené inhibitory protonové pumpy: Tipy pro praxi. *Klinická Onkologie*, 2018, 31, s. 409–413.
- Dupuis, L. – Sung, L. – Molassiotis, A., et al.: 2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children. *Supportive Care in Cancer*, 2017, 25, s. 323–331.
- Xiang, Z. – Chen, Y. – Ma, K., et al.: The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. *BMC Gastroenterology*, 2013, 13.
- Ikegami, T. – Matsuzaki, Y.: Ursodeoxycholic acid: Mechanism of action and novel clinical applications. *Hepatology Research*, 2008, 38, s. 123–131.
- Lazaridis, K. N. – Gores, G. J. – Lindor, K. D.: Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. *J Hepatol*, 2001, 35, s. 134–146.
- Bittner, B. – Richter, W. – Schmidt, J.: Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. *Bio Drugs*, 2018, 32, s. 425–440.

Diozen – lékový profil

MUDr. Helena Čermáková Cévní ambulance, Klinika transplantální chirurgie IKEM, Praha

- <http://www.sukl.cz/>
- Roztočil, K.: Diagnostika chronické žilní insuficience – Doporučený postup. IKEM, Praha.

Z první prospektivní studie podávání biologického přípravku v reálné klinické praxi plyne, že přípravek Nucala významně snižuje exacerbace těžkého eozinofilního astmatu – advertorial

Výsledky předběžné analýzy studie REALITI-A prezentované na kongresu Evropské respirační společnosti

- Data on file – Effectiveness and safety of mepolizumab in real-world clinical practice: the REALITI-A study, REF-27964.
- Khurana, S., et al.: Long-term safety and clinical benefit of mepolizumab in patients with the most severe eosinophilic asthma: The COSMEX Study. *Clin Ther*, 2019, 41, s. 2041–2056.
- RFNLA022718: Overview of Exacerbation Rates: MEA115666 (COLUMBA) and MEA112997 (DREAM), REF-2157.
- Nucala CZ SPC 2019, PI-4390.

Asthma bronchiale prizmatem moderní farmakoterapie

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- Coleman, C. I. – Limone, B. – Sobieraj, D. M., et al.: Dosing frequency and medication adherence in chronic disease. *J Manag Care Pharm*, 2012, 18, s. 527–539.
- Feehan, M. – Ranker, L. – Durante, R., et al.: Adherence to controller asthma medications: 6-month prevalence across a US community pharmacy chain. *J Clin Pharm Ther*, 2015, 40, s. 590–593.
- Busse, W.W. – Ring, J. – Huss-Marp, J. – Kahn, J.E.: A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma. *J Allergy Clin Immunol*, 2010, 125, s. 803–813.
- Ortega, H. G. – Liu, M. C. – Pavord, I. D., et al.: Mepolizumab treatment in patients with severe eosinophilic asthma. *N Engl J Med*, 2014, 371, s. 1198–1207.
- Allen, A. – Bareille, P. J. – Rousell, V. M.: Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. *Clin Pharmacokinet*, 2013, 52, s. 37–42.
- Salter, M. – Biggadike, K. – Matthews, J. L., et al.: Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. *Am J Physiol Lung Cell Mol Physiol*, 2007, 293, s. L660–L667.
- McCormack, P. L. – Scott, L. J.: Fluticasone furoate: intranasal use in allergic rhinitis. *Drugs*, 2007, 67, s. 1905–1915.
- O'Byrne, P. M. – Bleeker, E. R. – Bateman, E. D., et al.: Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. *Eur Respir J*, 2014, 43, s. 773–782.
- Busse, W.W. – O'Byrne, P. M. – Bleeker, E. R., et al.: Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients ≥ 12 years old with asthma: a randomised trial. *Thorax*, 2013, 68, s. 513–520.
- Oliver, A. – Bjermer, L. – Quinn, D., et al.: Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. *Allergy*, 2013, 68, s. 1136–1142.
- Oliver, A. – Van Buren, S. – Allen, A., et al.: Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma. *Clin Ther*, 2014, 36, s. 928–939.
- O'Byrne, P. M. – Bleeker, E. R. – Bateman, E. D., et al.: Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. *Eur Respir J*, 2014, 43, s. 773–782.
- Bateman, E. D. – O'Byrne, P. M. – Busse, W.W., et al.: Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. *Thorax*, 2014, 69, s. 312–319.
- Bleeker, E. R. – Lotvall, J. – O'Byrne, P. M., et al.: Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. *J Allergy Clin Immunol Pract*, 2014, 2, s. 553–561.
- Bernstein, D. I. – Bateman, E. D. – Woodcock, A., et al.: Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma. *J Asthma*, 2015, 52, s. 1073–1083.
- Lin, J. – Kang, J. – Lee, S. H., et al.: Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. *Respir Med*, 2015, 109, s. 44–53.
- Woodcock, A. – Bleeker, E. R. – Lotvall, J., et al.: Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. *Chest*, 2013, 144, s. 1222–1229.
- Albertson, T.E. – Richards, J.R. – Zeki, A. A.: The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience. *Thorax*, 2016, 10, s. 43–56.
- Dal Negro, R.W. – Bonadiman, L. – Turco, P.: Fluticasone furoate/vilanterol 92/22 microg once a day: a 12-month study on outcomes in mild to moderate asthma. *Thorax*, 2018, 12, 1753466618789894.
- Furuhashi, K. – Fujisawa, T. – Hashimoto, D., et al.: Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial. *J Asthma Allergy*, 2019, 12, s. 253–261.
- Dal Negro, R.W. – Bonadiman, L. – Turco, P.: Fluticasone furoate/vilanterol 92/22 mcg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 mcg b.i.d.: a 12-month comparison of outcomes in mild-to-moderate asthma. *Multidiscip Respir Med*, 2018, 13, s. 18.
- Lal, C. – Strange, C.: Evaluating fluticasone furoate + vilanterol for the treatment of chronic obstructive pulmonary disease (COPD). *Expert Opin Pharmacother*, 2019, 20, s. 1075–1085.
- Vallejo-Aparicio, L. A. – Peces-Barba, G. – Gil, A. – Huerta, H. A.: Cost-consequence analysis of fluticasone furoate/vilanterol 92/22 mcg for the management of COPD in the Spanish NHS. *Clinicoecon Outcomes Res*, 2018, 10, s. 501–510.
- Worsley, S. – Snowise, N. – Halpin, D. M. G., et al.: Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design. *ERJ Open Res*, 2019, 5.

Vitamin D – proč suplementovat?

prof. MUDr. Ondřej Topolčan, CSc. | doc. PharmDr. Radek Kučera, Ph.D. Oddělení imunochemické diagnostiky, Fakultní nemocnice Plzeň, Centrální laboratoř pro imunoanalýzu, Lékařská fakulta v Plzni, Univerzita Karlova

- Apperly, F. L.: The relation of solar radiation to cancer mortality in North America. *Cancer Res*, 1941, 1, s. 191–195.
- Broulík, P.: *O nemocnění způsobená poruchami kalciofosfátového metabolismu*. Praha, Maxdorf, 2017.
- Pfeifer, M. – Begerow, B. – Minne, H., et al.: Effects of a long term vitamin D and calcium supplementation on falls and parameters of muscle function in community dwelling older individuals. *Osteoporos Int*, 2009, 20, s. 315–322.
- Dirks-Naylor, A. J. – Lennon-Edwards, S.: The effects of vitamin D on skeletal muscle function and cellular signaling. *J Steroid Biochem Mol Biol*, 2011, 125, s. 159–168.
- Holick, M. F.: Vitamin D: extra skeletal health. *Endocrinol Metab Clin North Am*, 2010, 39, s. 381–400.
- Khaw, K. T. – Luben, R. – Wareham, N.: Serum 25 hydroxy vitamin D, mortality, and incident cardiovascular disease, respiratory disease, cancers, and fractures: a 13 y prospective population study. *Am J Clin Nutr*, 2014, 100, s. 1361–1370.
- Garland, C. F. – Kim, J. J. – Mohr, S. B., et al.: Metaanalysis of all cause mortality according to serum 25 hydroxy vitamin D. *Am J Public Health*, 2014, 104, s. e43–e50.
- Molero, I. G. – Martínez, G. R. – Morcillo, S., et al.: Vitamin D and incidence of diabetes: A prospective cohort study. *Clin Nutr*, 2012, 31, s. 571–573.
- Gezen, A. D. – Yilmazer, S. – Dursun, E.: Why vitamin D in Alzheimer disease? The hypothesis. *J Alzheimers Dis*, 2014, 40, s. 257–269.
- Huang, S. J. – Wang, X. H. – Liu, Z. D., et al.: Vitamin D deficiency and the risk of tuberculosis: a meta analysis. *Drug Des Devel Ther*, 2017, 11, s. 91–102.
- Denlinger, L. C. – King, T. S. – Cardet, J. C., et al.: Vitamin D supplementation and the risk of colds in patients with asthma. *Am J Respir Crit Care Med*, 2016, 193, s. 634–641.
- Aguilar, M. – Andronis, L. – Pallan, M., et al.: The economic case for prevention of population vitamin D deficiency: a modelling study using data from England and Wales. *Eur J Clin Nutr*, 20. 8. 2019.
- Darnton-Hill, I.: Public health aspects in the prevention and control of vitamin deficiencies. *Curr Dev Nutr*, 2019, 3, nzz075.
- Pilz, S. – März, W. – Cashman, K. D., et al.: Rationale and plan for vitamin D food fortification: a review and guidance paper. *Front Endocrinol*, 2018, 9, s. 373.

Fingolimod v léčbě relaps-remitující formy sclerosis multiplex –studie ASSESS

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- PubMed Health. Multiple sclerosis (MS). Dostupné z: <https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0024311/>, vyhledáno v říjnu 2018.
- Multiple sclerosis international federation. Types of MS. Dostupné z: <https://www.msif.org/about-ms/types-of-ms/>, vyhledáno v říjnu 2018.
- Multiple sclerosis international federation. Atlas of MS 2013. Dostupné z: <http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf>, vyhledáno v říjnu 2018.
- Waldman, A., et al.: Pediatric multiple sclerosis. *Neurology*, 2016, 87, s. 74–81.
- Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya® over Copaxone® in patients with relapsing remitting multiple sclerosis. Dostupné z: <https://www.novartis.com>, vyhledáno 1. 12. 2019.